Notification: Reference #jktl-icos-av can only be ordered together with reference #jktl-icos.

Agonist screening assay for ICOS/ICOS-L axis

InvivoGen offers a cellular assay specifically designed for screening antibody-, Fc-fusion protein-, or small-molecule agonists of the ICOS/ICOS-L immune checkpoint (IC) axis:

Jurkat-Lucia™ hICOS: Reporter T cells

Principle of ICOS cellular assay
(click to enlarge)

InvivoGen also offers:

• Antagonist screening assay for ICOS/ICOS-L axis
• hICOS-L-Fc fusion protein
• hICOS-Fc fusion protein

Inducible Co-stimulator (ICOS, CD278) is an immunostimulatory IC and a member of the CD28 superfamily. Expression of ICOS is rapidly induced in CD4+ and CD8+ T cells upon their activation, whereas its ligand ICOS-L (also known as CD275), is mostly expressed by antigen-presenting cells [1].

More details

Assay principle:

This assay relies on the monitored activation of Jurkat-Lucia™-ICOS cells which express a hICOS-CD3ζ fusion protein along with the Lucia luciferase reporter gene under the control of an ISG54 minimal promoter fused to six NFAT response elements. CD3ζ is a key component of the T-cell receptor (TCR) and CD3 complex that triggers TCR downstream signaling.
In the presence of a potent ICOS agonist, such as hICOS-L-Fc, hICOS-CD3ζ triggers NFAT activation and Lucia production. Activation of the reporter T cells can be readily measured using QUANTI-Luc™ 4 Lucia/Gaussia detection reagent (see Figures).

T-cell key features:

Stable hICOS-CD3ζ expression
NFAT-inducible Lucia luciferase reporter activity

InvivoGen also offers Jurkat-Raji ICOS/ICOS-L (Bio-IC™), a cellular assay for screening antagonists of the ICOS/ICOS-L axis.

Read our review on Immune Checkpoint Blockade

Learn more about Immune Checkpoint Antibodies.

Reference:

1. Amatore, F. et al. 2020. Role of ICOS in cancer immunotherapy. Expert Opin Biol Ther 20, 141-150.

Clear allRefined by

Products3

3 Search results: jktl-nfat-cd28